Mirikizumab pharmacokinetics and exposure-response relationships in patients with moderately to severely active ulcerative colitis: results from randomised phase 2 and phase 3 induction and maintenance trials

被引：0
|
作者：
Friedrich, S. [1 ]
Chua, L. [1 ]
Zhang, X. C. [1 ]
机构：
[1] Eli Lilly & Co, Immunol, Indianapolis, IN USA
来源：
JOURNAL OF CROHNS & COLITIS | 2023年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P519
引用
收藏
页码：646 / 646
页数：1
相关论文
共 50 条
  • [31] A PHASE 3 STUDY OF VEDOLIZUMAB FOR INDUCTION AND MAINTENANCE THERAPY IN JAPANESE PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
    Watanabe, Mamoru
    Motoya, Satoshi
    Watanabe, Kenji
    Ogata, Haruhiko
    Kanai, Takanori
    Matsui, Toshiyuki
    Suzuki, Yasuo
    Shikamura, Mitsuhiro
    Igeta, Masataka
    Oda, Kazunori
    Hori, Tetsuharu
    Araki, Takahiro
    Hibi, Toshifumi
    GASTROENTEROLOGY, 2018, 154 (06) : S380 - S381
  • [32] Mirikizumab Improves Mental and Physical Health Outcomes in Patients With Moderately to Severely Active Ulcerative Colitis: Results From the Phase 3 LUCENT-1 Induction and LUCENT-2 Maintenance Studies
    Sands, Bruce E.
    Feagan, Brian G.
    Gibble, Theresa Hunter
    Traxler, Kristina A.
    Morris, Nathan
    Li, Xingyuan
    Eastman, William J.
    Schreiber, Stefan
    Jairath, Vipul
    Armuzzi, Alessandro
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S528 - S529
  • [33] Mirikizumab Demonstrates Sustained Improvement in Fatigue in Patients with Moderately-to-Severely Active Ulcerative Colitis: Results From the Phase 3 LUCENT-1 Induction and LUCENT-2 Maintenance Studies
    Regueiro, Miguel
    Gibble, Theresa Hunter
    Bleakman, Alison Potts
    Li, Xingyuan
    Morris, Nathan
    Eastman, William J.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S518 - S519
  • [34] Mirikizumab Significantly Improves Abdominal Pain in Patients With Moderately-to-Severely Active Ulcerative Colitis: Results From the Phase 3 LUCENT-1 Induction and LUCENT-2 Maintenance Studies
    Loftus, Edward V.
    Gibble, Theresa Hunter
    Bleakman, Alison Potts
    Li, Xingyuan
    Morris, Nathan
    Hon, Emily
    Jairath, Vipul
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S533 - S534
  • [35] Population Pharmacokinetics and Exposure-Response Modeling Analyses of Ustekinumab in Adults With Moderately to Severely Active Ulcerative Colitis
    Xu, Yan
    Hu, Chuanpu
    Chen, Yang
    Miao, Xin
    Adedokun, Omoniyi J.
    Xu, Zhenhua
    Sharma, Amarnath
    Zhou, Honghui
    JOURNAL OF CLINICAL PHARMACOLOGY, 2020, 60 (07): : 889 - 902
  • [36] HISTOLOGIC REMISSION AND MUCOSAL HEALING IN A PHASE 2 STUDY OF MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
    Pai, Rish
    Canavan, James
    Tuttle, Jay
    Durante, Michael
    Arora, Vipin
    Milch, Catherine
    Harpaz, Noam
    D'Haens, Geert R.
    Sands, Bruce E.
    Sandborn, William J.
    GASTROENTEROLOGY, 2020, 158 (06) : S1187 - S1187
  • [37] Population Pharmacokinetics and Exposure-Response Modeling Analyses of Golimumab in Children With Moderately to Severely Active Ulcerative Colitis
    Xu, Yan
    Adedokun, Omoniyi J.
    Chan, Daphne
    Hu, Chuanpu
    Xu, Zhenhua
    Strauss, Richard S.
    Hyams, Jeffrey S.
    Turner, Dan
    Zhou, Honghui
    JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 59 (04): : 590 - 604
  • [38] PK, EFFICACY AND SAFETY OF MIRIKIZUMAB AS INDUCTION THERAPY IN PEDIATRIC PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2 SHINE-1 STUDY
    Kaplan, Jess
    Bousvaros, Athos
    Turner, Dan
    Dubinsky, Marla C.
    Komocsar, Wendy
    Larkin, Amy E.
    Johns, Jordan
    Zhang, Xin
    Little, Cheryl A.
    Crandall, Wallace
    Arora, Vipin
    Hyams, Jeffrey S.
    GASTROENTEROLOGY, 2023, 164 (06) : S169 - S169
  • [39] REDUCTION IN INFLAMMATORY BIOMARKERS IN A PHASE 2 STUDY OF MIRIKIZUMAB IN THE TREATMENT OF PATIENTS WITH MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS
    Sandborn, William J.
    Sands, Bruce E.
    Kobayashi, Taku
    Tuttle, Jay
    Schmitz, Jochen
    Durante, Michael
    Higgs, Richard E.
    Canavan, James
    Siegel, Robert
    Ferrante, Marc
    GASTROENTEROLOGY, 2019, 156 (06) : S1094 - S1095
  • [40] THE EFFICACY AND SAFETY OF GUSELKUMAB AS MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 QUASAR MAINTENANCE STUDY
    Rubin, David T.
    Allegretti, Jessica R.
    Panes, Julian
    Shipitofsky, Nicole
    Yarandi, Shadi
    Huang, Kuan-Hsiang G.
    Germinaro, Matthew
    Wilson, Rebbecca
    Zhang, Hongyan
    Feagan, Brian G.
    Hisamatsu, Tadakazu
    Lichtenstein, Gary R.
    Bressler, Brian
    Peyrin-Biroulet, Laurent
    Sands, Bruce E.
    Dignass, Axel
    GASTROENTEROLOGY, 2024, 166 (05) : S180 - S180
12345